Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The prognosis after relapse is generally poor, and no standard of care exists. We investigated the postrelapse outcomes of 149 patients who were initially treated in the Nordic Lymphoma Group trials, MCL2 or M...

Full description

Bibliographic Details
Main Authors: Christian Winther Eskelund, Kostas Dimopoulos, Arne Kolstad, Ingrid Glimelius, Riikka Räty, Lise Mette Rahbek Gjerdrum, Kristina Sonnevi, Pär Josefsson, Herman Nilsson-Ehle, Hans H. N. Bentzen, Unn Merete Fagerli, Outi Kuittinen, Jacob Haaber, Carsten Utoft Niemann, Lone Bredo Pedersen, Maria Torp Larsen, Christian Hartmann Geisler, Martin Hutchings, Mats Jerkeman, Kirsten Grønbæk
Format: Article
Language:English
Published: Wolters Kluwer 2021-01-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000510

Internet

http://journals.lww.com/10.1097/HS9.0000000000000510

Similar Items